A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies
Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This is an open label, Phase II, multi-center study designed to evaluate the effect of AVR118
when administered to patients with systemic symptoms related to recurrent or metastatic
cancers who may or may not be undergoing anti-cancer treatment. During the initial, induction
treatment phase of the study, AVR118, 4.0 mL, will be given subcutaneously each day for 28
days. Patients who respond to the trial period dosing will be eligible to continue on AVR118
if they and their physicians believe it would be beneficial, and if no safety concerns are
raised.